Citius PharmaceuticalsCTXR
About: Citius Pharmaceuticals Inc is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. The company is currently advancing four proprietary product candidates namely, LYMPHIR for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections, Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries, Halo-Lido, a topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids, and others.
Employees: 23
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
275% more call options, than puts
Call options by funds: $386K | Put options by funds: $103K
4.29% less ownership
Funds ownership: 13.06% [Q3] → 8.78% (-4.29%) [Q4]
50% less funds holding
Funds holding: 58 [Q3] → 29 (-29) [Q4]
79% less capital invested
Capital invested by funds: $11.8M [Q3] → $2.44M (-$9.37M) [Q4]
83% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 35
85% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 20
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
D. Boral Capital Jason Kolbert 28% 1-year accuracy 77 / 280 met price target | 500%upside $9 | Buy Maintained | 18 Feb 2025 |
Financial journalist opinion









